ECE2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL9867671	0.79	3/20
SCHEMBL9867682	0.79	3/20
SCHEMBL1784646	0.60	3/20
SCHEMBL1784650	0.60	3/20
SCHEMBL4711545	0.57	3/20
SCHEMBL4711546	0.57	3/20
SCHEMBL6087535	0.47	3/20
Dynasore (SCHEMBL847982)	1.00	2/20
Dynasore (SCHEMBL4570231)	1.00	2/20
SCHEMBL4570235	1.00	2/20
SCHEMBL10325190	1.00	2/20
SCHEMBL10325191	1.00	2/20
SCHEMBL4881278	0.83	2/20
SCHEMBL4570234	0.78	2/20
SCHEMBL1175103	0.78	2/20
SCHEMBL1175104	0.78	2/20
SCHEMBL5149469	0.78	2/20
SCHEMBL6635439	0.78	2/20
SCHEMBL8925781	0.78	2/20
SCHEMBL4570236	0.76	2/20

Clinical trials — most relevant to ECE2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers	PHASE4	COMPLETED
Telmisartan for Treatment of COVID-19 Patients	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Study to Verify the Effectiveness and Safety of Isothymol or Carvacrol Compound Against SARS-CoV-2 in COVID-19 Patients	PHASE2/PHASE3	COMPLETED
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension	PHASE3	COMPLETED
Correlation of Endothelial Function and Early Coronary Artery Disease in Humans	PHASE3	COMPLETED
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial	PHASE2/PHASE3	UNKNOWN
Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stem Cells	PHASE2	COMPLETED
Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)	PHASE2	UNKNOWN
Endothelin-Receptor Blockade in Coronary Heart Disease	PHASE1	COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications	PHASE1	UNKNOWN
Endothelial Dysfunction in Covid-19	nan	UNKNOWN
ACE2 Gender Differences in Stroke With COVID-19	nan	COMPLETED
Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)	nan	COMPLETED
Inter-individual Physiological Response to a Training and Detraining Period in Cardiometabolic Risk Factors Subjects	nan	COMPLETED
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium	nan	COMPLETED
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome	nan	UNKNOWN
Estrogen Therapy in Non-severe COVID-19 Patients	nan	UNKNOWN
Study of the Interaction Between the Cells Lining Blood Vessels and Angiotensin-Converting Enzyme	nan	COMPLETED
Embolism in COVID-19 Positive Patients	nan	UNKNOWN
Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.	nan	COMPLETED
Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)	nan	COMPLETED
NO-mediated Vascular Function in Covid-19 Patient	nan	COMPLETED
Role of Microparticles in Covid-19 Infection	nan	COMPLETED
Endothelial Effects of VEGF Inhibition In Vivo in Man	nan	COMPLETED
Effects of Nitrate-rich Beetroot Juice in Pregnant Women With High Blood Pressure	nan	UNKNOWN
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19	nan	UNKNOWN
Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?	nan	RECRUITING
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension	nan	COMPLETED
Mechanisms of Anti-VEGF Induced Hypertension	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ECE2 binder may also engage these)

Protein	Name	Similarity
F1N476	—	1.000	F1N476 →
P42893	—	1.000	P42893 →
P0DPE2	—	0.999	P0DPE2 →
B2RQR8	—	0.999	B2RQR8 →
P0DPD8	—	0.995	P0DPD8 →
P42891	—	0.994	P42891 →
MMEL1	Membrane metallo-endopeptidase-like 1	0.994	landscape →
P23276	—	0.993	P23276 →
P0C1T0	—	0.993	P0C1T0 →
ECE1	Endothelin-converting enzyme 1	0.993	landscape →
P0DPD9	—	0.992	P0DPD9 →
O95672	—	0.991	O95672 →
Q9JHL3	—	0.989	Q9JHL3 →
Q4PZA2	—	0.989	Q4PZA2 →
Q9JLI3	—	0.988	Q9JLI3 →
Q9JMI0	—	0.987	Q9JMI0 →
Q9EQF2	—	0.987	Q9EQF2 →
P97739	—	0.985	P97739 →
D0G895	—	0.984	D0G895 →
ERAP2	Endoplasmic reticulum aminopeptidase 2	0.982	landscape →
MME	Neprilysin	0.981	landscape →
Q6UWW8	—	0.981	Q6UWW8 →
Q3U435	—	0.981	Q3U435 →
O44857	—	0.980	O44857 →
A0A0B4K692	—	0.980	A0A0B4K692 →
Q8IS64	—	0.980	Q8IS64 →
Q8BG22	—	0.979	Q8BG22 →
O16796	—	0.979	O16796 →
Q9W436	—	0.979	Q9W436 →
Q96SM3	—	0.978	Q96SM3 →